CPAP Influence on Readily Available Inflammatory Markers in OSA-A Pilot Study

Int J Mol Sci. 2022 Oct 17;23(20):12431. doi: 10.3390/ijms232012431.

Abstract

Obstructive sleep apnea (OSA) is characterized by repetitive upper airway collapse, chronic hypoxia and a proinflammatory phenotype. The purpose of our study was to evaluate readily available inflammatory biomarkers (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count (WBC), red cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), WBC-to-MPV ratio (WMR) and lymphocyte-to-C-reactive protein ratio (LCR)) before and after CPAP in patients with moderate-severe OSA. We performed a prospective study that included patients with newly-diagnosed moderate-severe OSA. The control groups (patients without OSA and with mild OSA) were selected from the hospital polygraphy database. All subjects underwent routine blood panel, which was repeated in moderate-severe OSA patients after 8 weeks of CPAP. Our final study group included 31 controls, 33 patients with mild, 22 patients with moderate and 37 patients with severe OSA. CRP, ESR, NLR and WMR were correlated with OSA severity. After 8-week CPAP therapy, we documented a decrease in weight status, which remained statistically significant in both CPAP-adherent and non-adherent subgroups. Readily available, inexpensive inflammatory parameters can predict the presence of moderate-severe OSA, but are not influenced by short-term CPAP.

Keywords: C-reactive protein (CRP); continuous positive airway pressure (CPAP); inflammation; neutrophil-to-lymphocyte ratio (NLR); obstructive sleep apnea (OSA); platelet-to-lymphocyte ratio (PLR); red cell distribution width (RDW).

MeSH terms

  • Biomarkers
  • C-Reactive Protein* / metabolism
  • Humans
  • Pilot Projects
  • Prospective Studies
  • Sleep Apnea, Obstructive* / therapy

Substances

  • C-Reactive Protein
  • Biomarkers

Grants and funding

This research received no external funding.